PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation

– European Commission decides against adoption of negative opinion – – Translarna authorization remains active in Europe – – 2024 revenue guidance paused – WARREN, N.J., May 20, 2024 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the European Commission (EC)…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.